Claudio F. Sturino

2525 Avenue Marie Curie
Montreal, QC H4S2E1, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function.

Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 17, 2026

Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease.

Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease.

Journal: Journal of medicinal chemistry

Published: March 03, 2024

Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy.

Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy.

Journal: Journal of medicinal chemistry

Published: March 22, 2021

The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects.

The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects.

Journal: Communications biology

Published: June 05, 2020

Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.

Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.

Journal: Bioorganic & medicinal chemistry letters

Published: May 10, 2019

Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.

Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.

Journal: ACS medicinal chemistry letters

Published: February 11, 2016

Monitoring drug self-aggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical NMR strategy.

Monitoring drug self-aggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical NMR strategy.

Journal: Journal of medicinal chemistry

Published: August 08, 2013

Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.

Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.

Journal: Antimicrobial agents and chemotherapy

Published: April 03, 2013

Identification of potent and orally bioavailable nucleotide competing reverse transcriptase inhibitors: in vitro and in vivo optimization of a series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors.

Identification of potent and orally bioavailable nucleotide competing reverse transcriptase inhibitors: in vitro and in vivo optimization of a series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: March 11, 2013

Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors.

Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: December 19, 2012

Nucleotide competing reverse transcriptase inhibitors: discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitors.

Nucleotide competing reverse transcriptase inhibitors: discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: December 17, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026